Asset Details
Do you wish to reserve the book?
Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
Do you wish to request the book?
Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
2021
Overview
Anaplastic lymphoma kinase (ALK) rearrangements are drivers of a subset of non‐small cell lung cancer (NSCLC). The rapid progression of ALK inhibitors has significantly prolonged the progression‐free survival of patients with ALK gene‐sensitive mutations. However, the response of patients with rare ALK rearrangements to tyrosine kinase inhibitors remains unknown. Here, we report a rare case of striatin (STRN)‐ALK‐positive NSCLC showing primary resistance to first‐line therapy alectinib and limited clinical activity of crizotinib in the alectinib‐resistant setting. Here, we report a rare case of striatin (STRN)‐ALK‐positive NSCLC responding to crizotinib after the failure of alectinib. Our study highlights the heterogeneity in response of STRN‐ALK fusion to targeted drugs and provides clinical evidence of STRN‐ALK fusion responding to crizotinib.
Publisher
John Wiley & Sons Australia, Ltd,John Wiley & Sons, Inc,Wiley
Subject
/ Anaplastic Lymphoma Kinase - therapeutic use
/ Biopsy
/ Carbazoles - therapeutic use
/ Carcinoma, Non-Small-Cell Lung - drug therapy
/ Humans
/ Kinases
/ Lung Neoplasms - drug therapy
/ Male
/ Mutation
/ Patients
/ Piperidines - therapeutic use
/ Protein Kinase Inhibitors - pharmacology
/ Protein Kinase Inhibitors - therapeutic use
/ STRN‐ALK
/ Tyrosine
